Advertisement

Supportive Care in Cancer

, Volume 13, Issue 2, pp 104–108 | Cite as

Delayed emesis: moderately emetogenic chemotherapy

  • Fausto RoilaEmail author
  • David Warr
  • Rebecca A. Clark-Snow
  • Maurizio Tonato
  • Richard J. Gralla
  • Lawrence H. Einhorn
  • Jorn Herrstedt
Review Article

Abstract

Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT3 antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.

Keywords

Delayed emesis Moderately emetogenic chemotherapy Dexamethasone 5-HT3 antagonist 

References

  1. 1.
    Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819CrossRefPubMedGoogle Scholar
  2. 2.
    ASHP Commission on Therapeutics (1999) ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm 56:729–764Google Scholar
  3. 3.
    Barrenetxea G, Schneider J, Centeno MM, et al (1996) Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens. Cancer Chemother Pharmacol 38:471–475CrossRefPubMedGoogle Scholar
  4. 4.
    De Angelis V, Roila F, Sabbatini R, et al (2003) Cancer chemotherapy-induced delayed emesis: antiemetic prescriptions in clinical practice. Proc ASCO 22:739Google Scholar
  5. 5.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer 98:2473–2482CrossRefPubMedGoogle Scholar
  6. 6.
    ESMO Guidelines Task Force (2001). ESMO recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Ann Oncol 12:1059–1060CrossRefPubMedGoogle Scholar
  7. 7.
    Esseboom EU, Rojer RA, Borm JJ, et al (1995) Prophylaxis of delayed nausea and vomiting after cancer chemotherapy. Neth J Med 47:12–17CrossRefPubMedGoogle Scholar
  8. 8.
    Gralla RJ, Osoba D, Kris MG, et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994PubMedGoogle Scholar
  9. 9.
    Gralla R, Lichinitser M, Van der Vegt S, et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577CrossRefPubMedGoogle Scholar
  10. 10.
    Grunberg SM, Hansen M, Deuson R, et al (2002) Incidence and impact of nausea and vomiting with modern antiemetics: perception versus reality. Proc. ASCO 21:250aGoogle Scholar
  11. 11.
    Herrstedt J, Sigsgaard T, Boesgaard M, et al (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. New Engl J Med 328:1076–1080CrossRefPubMedGoogle Scholar
  12. 12.
    Inoue A, Yamada Y, Matsumura Y, et al (2003) Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11:528–532CrossRefPubMedGoogle Scholar
  13. 13.
    Italian Group for Antiemetic Research (1997) Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? Ann Oncol 8:561–567CrossRefPubMedGoogle Scholar
  14. 14.
    Italian Group for Antiemetic Research (1998) Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 9:759–765CrossRefPubMedGoogle Scholar
  15. 15.
    Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554–1559CrossRefPubMedGoogle Scholar
  16. 16.
    Italian Group for Antiemetic Research (2004) Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 22:725–729CrossRefPubMedGoogle Scholar
  17. 17.
    Italian Group for Antiemetic Research (2004) Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Support Care Cancer 12(6):446–453CrossRefPubMedGoogle Scholar
  18. 18.
    Kaizer L, Warr D, Hoskins P, et al (1994) Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:1050–1057PubMedGoogle Scholar
  19. 19.
    Koo WH, Ang PT (1996) Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7:71–74PubMedGoogle Scholar
  20. 20.
    Pater JL, Lofters WS, Zee B, et al (1997) The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8:181–185CrossRefPubMedGoogle Scholar
  21. 21.
    Stewart A, McQuade B, Cronje JDE, et al (1995) Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide induced emesis in outpatients: a multicentre, double-blind, double dummy, randomised, parallel group study. Oncology 52:202–210PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Fausto Roila
    • 1
    Email author
  • David Warr
    • 2
  • Rebecca A. Clark-Snow
    • 3
  • Maurizio Tonato
    • 4
  • Richard J. Gralla
    • 5
  • Lawrence H. Einhorn
    • 6
  • Jorn Herrstedt
    • 7
  1. 1.Medical Oncology DivisionPoliclinico HospitalPerugiaItaly
  2. 2.Department of Medical Oncology and HematologyPrincess Margaret HospitalTorontoCanada
  3. 3.University of Kansas Cancer CenterKansas CityUSA
  4. 4.Medical Oncology DivisionPoliclinico HospitalPerugiaItaly
  5. 5.New York Lung Cancer AllianceNew YorkUSA
  6. 6.Walther Cancer InstituteIndianapolisUSA
  7. 7.Department of OncologyCopenhagen University Hospital HerlevCopenhagenDenmark

Personalised recommendations